Recently, the phase 3 IMpassion130 trial showed a significant benefit in progression-free survival (PFS) for inoperable metastatic TNBC patients who were treated in first-line with the combination of atezolizumab and nab-paclitaxel (HR 0.80; P=0.002) [1]. This benefit was observed both in the intention-to-treat (ITT) population and in PD-L1 immune cell-positive patients. Median overall survival (OS) in the ITT population was 21.0 months for the atezolizumab-treated patients and 18.7 months in the placebo arm (HR 0.87; P=0.77); 3-year OS was 28% and 25%, respectively [2]. Median OS in the PD-L1-positive patients was 25.4 months in the atezolizumab arm versus 17.9 months with placebo (HR 0.67; not formally tested); 3-year OS was 36% and 22%, respectively. In the PD-L1-negative population, there was no OS benefit for atezolizumab.
In contrast, results from the first interim analysis of the phase 3 IMpassion131 trial do not show a significant improvement of PFS or OS in the PD-L1-positive population [3]. In this trial, 651 patients with metastatic or unresectable TNBC were randomised (2:1) to first-line treatment with atezolizumab plus paclitaxel or placebo plus paclitaxel. Median PFS was 6.0 months in the atezolizumab arm and 5.7 months in the placebo arm (HR 0.82; P=0.20). The lack of benefit of atezolizumab in IMpassion131 was not due to a difference in exposure to paclitaxel.
- Schmid P, et al. N Engl J Med 2018;379:2108-2121.
- Emens LA, et al. IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. ESMO 2020 Virtual Meeting, abstract LBA16.
- Miles DW, et al. Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). ESMO 2020 Virtual Meeting, abstract LBA15.
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Second-line sacituzumab govitecan improves survival in metastatic TNBC Next Article
Prognostic value of tumour infiltrating lymphocytes in young TNBC patients »
« Second-line sacituzumab govitecan improves survival in metastatic TNBC Next Article
Prognostic value of tumour infiltrating lymphocytes in young TNBC patients »
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
Related Articles
November 25, 2020
Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence
November 25, 2020
Treatment of recurrent ovarian cancer
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy